Breaking News Instant updates and real-time market news.

TSRO

TESARO

$117.91

18.65 (18.79%)

, MYGN

Myriad Genetics

$18.87

-2.475 (-11.60%)

13:25
10/11/16
10/11
13:25
10/11/16
13:25

TESARO failed to block Myriad press release, Bloomberg reports

A Manhattan district judge denied TESARO's (TSRO) attempt to block its partner Myriad Genetics (MYGN) from releasing a press release on the niraparib trial results. Both companies issued press releases on October 8.

TSRO

TESARO

$117.91

18.65 (18.79%)

MYGN

Myriad Genetics

$18.87

-2.475 (-11.60%)

  • 06

    Nov

  • 11

    Jan

TSRO TESARO
$117.91

18.65 (18.79%)

10/10/16
RBCM
10/10/16
NO CHANGE
RBCM
TESARO price target raised to $128 from $122 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on TESARO after ovarian cancer patients taking the company's Niraparib drug responded better than expected. Butt said that the drug benefited the patients regardless of BRCA or HRD biomarker status. He keeps an Outperform rating on the stock.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
TESARO price target raised to $120 from $105 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating
10/10/16
FBCO
10/10/16
NO CHANGE
Target $122
FBCO
Outperform
TESARO price target raised to $122 on Niraparib data at Credit Suisse
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Strong Buy
TESARO price target raised to $120 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.
MYGN Myriad Genetics
$18.87

-2.475 (-11.60%)

10/10/16
10/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Honeywell (HON) downgraded to Buy from Conviction Buy at Goldman with analyst Christopher Glynn lowering his Q3 Earnings Per Share expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. 2. United Technologies (UTX) downgraded to Neutral from Buy at Citi with analyst Jason Gursky saying he sees three issues limiting share upside over the next twelve-plus months. 3. PNC Financial (PNC) was downgraded to Neutral from Buy at Nomura while the firm downgraded Fifth Third (FITB) to Reduce from Neutral. 4. Myriad Genetics (MYGN) downgraded to Sell from Neutral at Ladenburg with analyst Kevin DeGeeter citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. 5. HSN, Inc. (HSNI) downgraded to Hold from Buy at Craig-Hallum with analyst Alex Fuhrman saying his channel checks indicate continued weakness in the third quarter, with particular weakness in jewelry and consumer electronics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
PIPR
10/10/16
NO CHANGE
PIPR
Neutral
TESARO data suggest Myriad test not necessary, says Piper Jaffray
Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.

TODAY'S FREE FLY STORIES

DE

Deere

$101.50

-1.2 (-1.17%)

13:12
12/04/16
12/04
13:12
12/04/16
13:12
Periodicals
Deere could keep climbing, Barron's says »

Deere stock recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$9.81

0.28 (2.94%)

, GME

GameStop

$24.27

-0.37 (-1.50%)

12:57
12/04/16
12/04
12:57
12/04/16
12:57
Periodicals
Corporate tax cut can't save all retailers, Barron's says »

Though President-elect…

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

12:40
12/04/16
12/04
12:40
12/04/16
12:40
Periodicals
Callaway Golf investors should take profits, Barron's says »

It "looks like a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVC

Entravision

12:36
12/04/16
12/04
12:36
12/04/16
12:36
Periodicals
Entravision shares could reach $9, Barron's says »

Hispanic-focused…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GOOG

Alphabet

$750.50

2.58 (0.34%)

, GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

12:26
12/04/16
12/04
12:26
12/04/16
12:26
Periodicals
Barron's picks top ten stocks for 2017 »

Selecting its ten…

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AAPL

Apple

$109.90

0.41 (0.37%)

C

Citi

$56.02

-1.25 (-2.18%)

DAL

Delta Air Lines

$48.31

0.54 (1.13%)

DTEGY

Deutsche Telekom

$15.65

0.14 (0.90%)

MRK

Merck

$61.13

0.37 (0.61%)

NVS

Novartis

$68.17

0.42 (0.62%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

UL

Unilever; also tag UN

$39.67

0.5 (1.28%)

UN

Unilever; also tag UL

$39.47

0.35 (0.89%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 15

    Jan

  • 26

    Jan

  • 08

    Mar

  • 13

    Mar

TWTR

Twitter

$17.93

-0.1 (-0.55%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Periodicals
Early Twitter investor Sacca would 'love' to see the company sold, CNBC reports »

One of the earliest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.